A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Renaissance Technologies LLC holds 169,400 shares of ADPT stock, worth $1.08 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
169,400
Previous 151,800 11.59%
Holding current value
$1.08 Million
Previous $549,000 57.92%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.37 - $5.12 $59,312 - $90,112
17,600 Added 11.59%
169,400 $867,000
Q2 2024

Aug 09, 2024

BUY
$2.34 - $3.96 $232,167 - $392,899
99,217 Added 188.69%
151,800 $549,000
Q1 2024

May 13, 2024

BUY
$2.88 - $4.8 $151,439 - $252,398
52,583 New
52,583 $169,000
Q3 2023

Nov 14, 2023

SELL
$5.07 - $8.44 $1.46 Million - $2.42 Million
-287,300 Reduced 84.87%
51,200 $279,000
Q2 2023

Aug 11, 2023

SELL
$6.19 - $8.78 $343,545 - $487,289
-55,500 Reduced 14.09%
338,500 $2.27 Million
Q1 2023

May 12, 2023

SELL
$7.8 - $10.11 $170,040 - $220,398
-21,800 Reduced 5.24%
394,000 $3.48 Million
Q4 2022

Feb 13, 2023

SELL
$6.26 - $9.34 $262,920 - $392,280
-42,000 Reduced 9.17%
415,800 $3.18 Million
Q3 2022

Nov 14, 2022

SELL
$6.5 - $12.67 $186,550 - $363,629
-28,700 Reduced 5.9%
457,800 $3.26 Million
Q2 2022

Aug 12, 2022

BUY
$6.4 - $14.73 $197,760 - $455,157
30,900 Added 6.78%
486,500 $3.94 Million
Q1 2022

May 13, 2022

BUY
$10.12 - $28.9 $4.61 Million - $13.2 Million
455,600 New
455,600 $6.32 Million
Q2 2021

Aug 13, 2021

SELL
$32.22 - $44.59 $5.16 Million - $7.14 Million
-160,200 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$37.26 - $67.74 $5.97 Million - $10.9 Million
160,200 New
160,200 $6.45 Million

Others Institutions Holding ADPT

About Adaptive Biotechnologies Corp


  • Ticker ADPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 142,872,992
  • Market Cap $913M
  • Description
  • Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...
More about ADPT
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.